Zydus Nycomed Commissions API Manufacturing Facility
To start with, the plant will be manufacturing Pantoprazole, Urapidil and Lornoxicam. By 2011, the company will produce eight additional APIs. The newly commissioned facilities mark the transition of Zydus Nycomed from an intermediate manufacturer to a full-fledged API manufacturer.
The plant earlier provided high quality Key Starting Materials for manufacturing Pantoprazole. Besides other APIs, the expanded facility will now manufacture the active ingredient of Pantoprazole, Nycomed’s key product for acid-related gastrointestinal diseases, making it one of the largest end-to-end manufacturers of this API in India.
Pankaj Patel, chairman and managing director of Zydus Cadila, said: “This milestone marks a new beginning in the partnership that has been evolving and growing from strength to strength over the years.
“Zydus Nycomed has become a global hub of excellence with its high standards of quality, precision in manufacturing and customer service. The expansion of operations adds newer dimensions to this partnership and opens up new paths to excellence and growth.”
Hakan Bjorklund, CEO of Nycomed, said: “Today’s plant opening is a significant step forward to getting high quality APIs in Nycomed’s branded generic portfolio produced at competitive costs.
“Having a time-tested and solid partnership in place, like we have with Zydus Cadila, gives me confidence we will continue to achieve our goal of getting medicines that matter to those who need them.”
Will the expansion benefit the firm?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.